KR102078999B1 - 타펜타돌의 적정 - Google Patents

타펜타돌의 적정 Download PDF

Info

Publication number
KR102078999B1
KR102078999B1 KR1020177037810A KR20177037810A KR102078999B1 KR 102078999 B1 KR102078999 B1 KR 102078999B1 KR 1020177037810 A KR1020177037810 A KR 1020177037810A KR 20177037810 A KR20177037810 A KR 20177037810A KR 102078999 B1 KR102078999 B1 KR 102078999B1
Authority
KR
South Korea
Prior art keywords
dose
days
tapentadol
interval
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177037810A
Other languages
English (en)
Korean (ko)
Other versions
KR20180004839A (ko
Inventor
클라우디아 랑게
페르디난트 롬바우트
Original Assignee
그뤼넨탈 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38123877&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102078999(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 그뤼넨탈 게엠베하 filed Critical 그뤼넨탈 게엠베하
Publication of KR20180004839A publication Critical patent/KR20180004839A/ko
Application granted granted Critical
Publication of KR102078999B1 publication Critical patent/KR102078999B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Adhesive Tapes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020177037810A 2007-04-23 2008-04-21 타펜타돌의 적정 Active KR102078999B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07008218A EP1985292A1 (en) 2007-04-23 2007-04-23 Titration of tapentadol
EP07008218.5 2007-04-23
PCT/EP2008/003178 WO2008128740A1 (en) 2007-04-23 2008-04-21 Titration of tapentadol

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR20157003922A Division KR20150027840A (ko) 2007-04-23 2008-04-21 타펜타돌의 적정

Publications (2)

Publication Number Publication Date
KR20180004839A KR20180004839A (ko) 2018-01-12
KR102078999B1 true KR102078999B1 (ko) 2020-02-19

Family

ID=38123877

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020177037810A Active KR102078999B1 (ko) 2007-04-23 2008-04-21 타펜타돌의 적정
KR20157003922A Ceased KR20150027840A (ko) 2007-04-23 2008-04-21 타펜타돌의 적정
KR1020097024357A Ceased KR20100017267A (ko) 2007-04-23 2008-04-21 타펜타돌의 적정

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR20157003922A Ceased KR20150027840A (ko) 2007-04-23 2008-04-21 타펜타돌의 적정
KR1020097024357A Ceased KR20100017267A (ko) 2007-04-23 2008-04-21 타펜타돌의 적정

Country Status (21)

Country Link
US (4) US20090012180A1 (https=)
EP (5) EP1985292A1 (https=)
JP (4) JP5933176B2 (https=)
KR (3) KR102078999B1 (https=)
CN (1) CN101730530B (https=)
AT (1) ATE534378T1 (https=)
AU (1) AU2008241013B2 (https=)
CA (1) CA2683786C (https=)
CY (1) CY1112320T1 (https=)
DK (1) DK2148670T3 (https=)
ES (1) ES2378255T3 (https=)
HR (1) HRP20120147T1 (https=)
IL (1) IL201479A (https=)
MX (1) MX2009011444A (https=)
NZ (1) NZ580415A (https=)
PL (1) PL2148670T3 (https=)
PT (1) PT2148670E (https=)
RU (1) RU2472497C2 (https=)
SI (1) SI2148670T1 (https=)
WO (1) WO2008128740A1 (https=)
ZA (1) ZA200907355B (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1985292A1 (en) 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
RU2673882C1 (ru) * 2008-10-30 2018-12-03 Грюненталь Гмбх Новые и эффективные лекарственные формы тапентадола
US8870876B2 (en) * 2009-02-13 2014-10-28 Tarsus Medical Inc. Methods and devices for treating hallux valgus
US8277459B2 (en) * 2009-09-25 2012-10-02 Tarsus Medical Inc. Methods and devices for treating a structural bone and joint deformity
US8652141B2 (en) 2010-01-21 2014-02-18 Tarsus Medical Inc. Methods and devices for treating hallux valgus
EP2566461A2 (de) * 2010-05-05 2013-03-13 Ratiopharm GmbH Festes tapentadol in nicht-kristalliner form
US8696719B2 (en) 2010-06-03 2014-04-15 Tarsus Medical Inc. Methods and devices for treating hallux valgus
DK2588093T3 (en) * 2010-06-30 2016-08-29 Gruenenthal Gmbh Tapentadol FOR USE IN THE TREATMENT OF irritable bowel syndrome
CN110015955A (zh) * 2010-07-23 2019-07-16 格吕伦塔尔有限公司 3-(3-二甲基氨基-1-乙基-2-甲基-丙基)-苯酚的盐或共晶体
CN101948397A (zh) * 2010-09-07 2011-01-19 天津泰普药品科技发展有限公司 镇痛药他喷他多重要中间体的制备方法
ES2910085T3 (es) 2011-03-04 2022-05-11 Gruenenthal Gmbh Composición farmacéutica acuosa semisólida que contiene tapentadol
CN103501775A (zh) * 2011-03-04 2014-01-08 格吕伦塔尔有限公司 他喷他多的胃肠外给药
MX388963B (es) 2011-03-04 2025-03-20 Gruenenthal Gmbh Formulacion farmaceutica acuosa de tapentadol para administracion oral
EP3607943B1 (en) * 2011-04-05 2024-09-11 Grünenthal GmbH Tapentadol for use in treating pain associated with trigeminal neuralgia
ES2703282T3 (es) 2011-04-05 2019-03-07 Gruenenthal Gmbh Tapentadol para prevenir la cronificación del dolor
US20120277319A1 (en) 2011-04-29 2012-11-01 Gruenenthal Gmbh Use of Tapentadol for Inhibiting and/or Treating Depression and Anxiety
CA2901802C (en) * 2013-03-15 2021-03-02 Mallinckrodt Llc Abuse deterrent solid dosage form for immediate release with functional score
EP2845625A1 (en) * 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
PE20171651A1 (es) 2015-03-27 2017-11-13 Gruenenthal Chemie Formulacion estable para administracion parenteral de tapentadol
PT3302454T (pt) * 2015-05-26 2021-04-01 Technophage Investig E Desenvolvimento Em Biotecnologia Sa Composições para utilização no tratamento da doença de parkinson e distúrbios associados
JP7373904B2 (ja) * 2016-02-29 2023-11-06 パーク・セラピューティクス・インコーポレイテッド セブラノパドールの滴定
EP3515412B1 (en) 2016-09-23 2025-04-23 Grünenthal GmbH Stable formulation for parenteral administration of tapentadol
ES3010208T3 (en) 2020-03-16 2025-04-01 Gruenenthal Gmbh Scored tablet comprising tapentadol
WO2022194941A1 (en) * 2021-03-17 2022-09-22 Actelion Pharmaceuticals Ltd Pharmaceutical dosage system
EP4333820A1 (en) * 2021-05-07 2024-03-13 Grünenthal GmbH Tapentadol for treating neuropathic pain in covid-19 patients

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
JPS6327805A (ja) 1986-07-21 1988-02-05 Sumitomo Electric Ind Ltd 光フアイバの接続用部材及びそれを用いた接続方法
DE4426245A1 (de) * 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US6339105B1 (en) * 1999-10-12 2002-01-15 Ortho-Mcneil Pharmaceutical, Inc. Analgesic regimen
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
DK1572167T3 (da) 2002-12-13 2008-10-13 Euro Celtique Sa Transdermal buprenophindoseringsbehandlingsplan for analgesi
US7413749B2 (en) * 2003-03-11 2008-08-19 Purdue Pharma L.P. Titration dosing regimen for controlled release tramadol
DE102007019417A1 (de) 2007-04-23 2008-11-13 Grünenthal GmbH Tapentadol zur Schmerzbehandlung bei Arthrose
EP1985292A1 (en) * 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol

Also Published As

Publication number Publication date
CY1112320T1 (el) 2015-12-09
MX2009011444A (es) 2009-11-05
IL201479A (en) 2016-04-21
US20090012180A1 (en) 2009-01-08
CA2683786C (en) 2021-10-26
JP5933176B2 (ja) 2016-06-08
WO2008128740A8 (en) 2010-06-17
CN101730530B (zh) 2013-10-23
AU2008241013B2 (en) 2013-06-20
RU2009142940A (ru) 2011-05-27
EP2148670B1 (en) 2011-11-23
IL201479A0 (en) 2010-05-31
JP2018030864A (ja) 2018-03-01
EP3603630A1 (en) 2020-02-05
ZA200907355B (en) 2010-08-25
KR20150027840A (ko) 2015-03-12
US20160074342A1 (en) 2016-03-17
SI2148670T1 (sl) 2012-03-30
RU2472497C2 (ru) 2013-01-20
EP3143993A1 (en) 2017-03-22
WO2008128740A1 (en) 2008-10-30
JP2019131598A (ja) 2019-08-08
AU2008241013A1 (en) 2008-10-30
EP2422778A1 (en) 2012-02-29
US20190290603A1 (en) 2019-09-26
ES2378255T3 (es) 2012-04-10
NZ580415A (en) 2012-04-27
KR20180004839A (ko) 2018-01-12
PT2148670E (pt) 2012-01-24
CA2683786A1 (en) 2008-10-30
CN101730530A (zh) 2010-06-09
JP2010531296A (ja) 2010-09-24
EP1985292A1 (en) 2008-10-29
PL2148670T3 (pl) 2012-04-30
KR20100017267A (ko) 2010-02-16
US11344512B2 (en) 2022-05-31
DK2148670T3 (da) 2012-03-12
ATE534378T1 (de) 2011-12-15
JP2016128468A (ja) 2016-07-14
HRP20120147T1 (hr) 2012-03-31
EP2148670A1 (en) 2010-02-03
HK1140940A1 (en) 2010-10-29
US20170079938A1 (en) 2017-03-23

Similar Documents

Publication Publication Date Title
KR102078999B1 (ko) 타펜타돌의 적정
EP2701693B1 (en) Tapentadol for preventing and treating depression and anxiety
JP5784189B2 (ja) 蝸牛性耳鳴の治療用１−アミノ−アルキルシクロヘキサン誘導体
WO2008156749A1 (en) Combination therapy for depression
US10500170B2 (en) Composition and method for treating neurological disease
US20040122065A1 (en) Pharmaceutical compositions and dosage forms for buccal and sublingual delivery of tizanidine and methods of administering tizanidine sublingually or buccally
JP6084931B2 (ja) ストレス又は急性聴力損失に関連する耳鳴の治療又は予防のためのネラメキサン
HK1233916A1 (en) Titration of tapentadol
HK1140940B (en) Titration of tapentadol
HK1143536A (en) Interval therapy for the treatment of tinnitus
HK1145151A (en) 1-amino-alkylcyclohexane derivatives for the treatment of cochlear tinnitus
WO2008106569A1 (en) Renin inhibitors for the treatment of hypertension in patients with high sodium diet

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 7